Albion Enterprise VCT PLC, a United Kingdom-based venture capital trust founded in 2006 and headquartered at 1 Benjamin Street, London, invests in a diversified portfolio of higher-growth businesses across sectors including technology, healthcare, fintech, renewable energy, software, and education; its core offerings provide investors with a regular income stream through bi-annual dividends targeting around 5% yield of net asset value alongside long-term capital growth via equity and debt in early-stage and growth companies such as Ionate in hybrid transformers, Open Trade Technology in embedded finance, Total Access Health in healthcare platforms, Labrys Group in defence communications, Panaseer in cybersecurity, Convertr Media in customer acquisition, and GX Molecular in single-cell sequencing. The trust, managed by Albion Capital Group LLP, operates primarily in the UK market, backing entrepreneurs with follow-on and new investments totaling millions in recent periods. In late 2024 and 2025, it completes a major merger with Albion Development VCT PLC, doubling net assets to over 278 million pounds, announces new portfolio additions like Evaro and Revgentic, pays dividends including 2.91 pence in August 2025 with cumulative payouts since launch reaching 97.98 pence, and reports NAV of 112.81 pence as of June 2025 alongside an 8.2% shareholder return for the year.